ID   LAMA84-r
AC   CVCL_DP57
DR   ATCC; CRL-3348
DR   Wikidata; Q54901917
RX   PubMed=10910924;
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC=CRL-3348
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11
ST   D5S818: 11,12
ST   D7S820: 11
ST   TH01: 7
ST   TPOX: 10
ST   vWA: 14,17
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0388 ! LAMA-84
SX   Female
AG   29Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 14
//
RX   PubMed=10910924; DOI=10.1182/blood.V96.3.1070;
RA   Mahon, Francois-Xavier
RA   Deininger, Michael W.N.
RA   Schultheis, Beate
RA   Chabrol, Jerome
RA   Reiffers, Josy
RA   Goldman, John Michael
RA   Vaz de Melo, Junia
RT   "Selection and characterization of BCR-ABL positive cell lines with
RT   differential sensitivity to the tyrosine kinase inhibitor STI571:
RT   diverse mechanisms of resistance.";
RL   Blood 96:1070-1079(2000).
//